New Zealand markets open in 7 hours 39 minutes

  • NZX 50

    11,316.46
    +49.07 (+0.44%)
     

  • NZD/USD

    0.6478
    +0.0067 (+1.05%)
     

  • ALL ORDS

    7,398.90
    +7.90 (+0.11%)
     

  • OIL

    110.16
    -0.12 (-0.11%)
     

  • GOLD

    1,854.40
    +12.30 (+0.67%)
     

Global Pulmonary Arterial Hypertension (2021 to 2027) - by Drug Class, Route of Administration, Distribution Mode, and Geography - ResearchAndMarkets.com

·3-min read

DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Pulmonary Arterial Hypertension Market is estimated to be USD 8.1 Bn in 2021 and is expected to reach USD 11.68 Bn by 2027, growing at a CAGR of 6.2%.

Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH). Several Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the growth rate of the global pulmonary arterial hypertension market.

However, discontinuing of drug production by major players during clinical trials and stringent regulations by Government, lack of awareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to hinder the market growth. Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.

Market Dynamics

Drivers

  • Growing Burden of Pulmonary Arterial Hypertension

  • Government and Private Support for the Development of Orphan Drugs

  • Growing Geriatric Population

Restraints

  • Patent Expiration of Key Molecules

  • Side Effects Associated with the Drugs

  • Lack of Awareness among People in Developing Countries

Challenges

  • High Costs of Diagnosis and Treatment

  • Lack of Awareness

  • Expiry of Patents

Opportunities

  • Advance Oral Drugs for Pulmonary Arterial Hypertension

  • Technology Advancements such as Biomaker and New Gene Therapy for the Treatment

The Global Pulmonary Arterial Hypertension is segmented based on Drug Class, Route of Administration, Distribution Mode, and Geography.

Global Pulmonary Arterial Hypertension Market, By Drug Class

  • Introduction

  • Prostacyclin and Prostacyclin Analogs

  • Soluble Guanylate Cyclase (SGC) Stimulators

  • Endothelin Receptor Antagonists (ERAs)

  • Phosphodiesterase 5 (Pde-5)

  • Calcium Channel Blockers

  • Others

Global Pulmonary Arterial Hypertension Market, By Route of Administration

  • Introduction

  • Oral

  • Injectable

Global Pulmonary Arterial Hypertension Market, By Distribution Mode

  • Introduction

  • Hospital Pharmacy

  • Online Pharmacy

  • Retail Pharmacy

Global Pulmonary Arterial Hypertension Market, By Geography

  • Introduction

  • North America

  • South America

  • Europe

  • Asia Pacific

  • The Middle East and Africa

Companies Mentioned

  • Gilead Sciences, Inc.

  • United Therapeutics Corporation

  • Novartis International AG

  • GlaxoSmithKline Plc. (GSK)

  • Pfizer, Inc.

  • Dong-A ST Co., Ltd.

  • Merck Sharp & Dohme Corp.

  • Bayer HealthCare AG

  • Arena Pharmaceuticals

  • Actelion Pharmaceuticals Ltd

  • Daiichi Sankyo Company, Limited

  • Gilead Sciences

  • Johnson & Johnson

  • AstraZeneca

  • Bristol-Myers Squibb Company

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Pulmonary Arterial Hypertension Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.

  • The report also contains the competitive analysis using the Competitive Quadrant, the publisher's Proprietary competitive positioning tool.

For more information about this report visit https://www.researchandmarkets.com/r/6b7u5l

View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005220/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting

Latest stories

  • Pistachio Market Report 2022 - Global Forecast to 2026: Increasing Potential Application from Nutraceuticals & Rising Demand from the Food Processing Industry - ResearchAndMarkets.com

    DUBLIN, May 23, 2022--The "Pistachio Market Research Report by Product (In-shelled and Shelled), Distribution, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

  • Griffin Global Asset Management Announces the Delivery of an Airbus A321neo Aircraft to IndiGo

    DUBLIN, Ireland, May 23, 2022 (GLOBE NEWSWIRE) -- Griffin Global Asset Management (“Griffin”) is pleased to announce the delivery of an Airbus A321neo aircraft to InterGlobe Aviation Ltd. (“IndiGo”), a low-cost airline based in India. This aircraft is the first of five purchase and leaseback transactions mandated for Airbus A321neo aircraft scheduled to be delivered to IndiGo during May and June of 2022. “We could not be more pleased to add IndiGo to our growing list of airline partners. They ha

  • CDB Aviation Promotes Fiona Scott to Newly Created Role of Chief People Officer

    DUBLIN, May 23, 2022--CDB Aviation, a wholly owned Irish subsidiary of China Development Bank Financial Leasing Co., Limited ("CDB Leasing"), announced today the promotion of Fiona Scott to the newly created role of Chief People Officer.

  • Howie Mandel Joins NOCD to Change the OCD Conversation

    CHICAGO, May 23, 2022--NOCD and Howie Mandel join together to launch the #KnowOCD campaign.

  • Late-breaking Results Show Efficacy for CCM in Patients With HFpEF

    Investigators Report Positive Findings From Feasibility Study of CCM in Heart Failure With Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 CongressMADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a late-breaking presentation of results from the CCM-HFpEF Piloty Study, which is the largest clinical trial to date studyi

  • Big Banks Lead Gains in Stocks; Treasuries Retreat: Markets Wrap

    (Bloomberg) -- Stocks rose after President Joe Biden signaled he’d reconsider China tariffs imposed by the Trump administration. The dollar and bonds fell.Most Read from BloombergWalmart’s Troubles Should Have Everyone on High AlertBroadcom in Talks to Acquire Cloud Company VMwareStocks Rise, Bonds Fall as Risk Appetite Returns: Markets WrapBiden Misspeaks on Taiwan, Says US Military Would InterveneA $5 Trillion ‘Wealth Shock’ Is Cracking Americans’ Nest EggsBig banks led gains in the S&P 500 af

  • Barrell Craft Spirits® Unveils BCS Gold Label Seagrass

    LOUISVILLE, Ky., May 23, 2022--Barrell Craft Spirits® (BCS), the award-winning independent blender of unique aged, cask-strength sourced whiskey and rum, will introduce BCS Gold Label Seagrass, the pinnacle of the BCS Seagrass Series, which also includes Barrell Seagrass and the limited-release BCS Gray Label Seagrass.

  • Egypt court sentences pro-democracy activist to four years

    An Egyptian court on Monday sentenced a pro-democracy activist to four years in prison for disseminating false news, a defense lawyer said. The court of misdemeanors in Cairo convicted Yahia Hussein Abdel-Hadi, a co-founder of the Civil Democratic Movement, an opposition coalition of liberal and left-leaning parties, of “deliberately disseminating false news inside and outside” Egypt, according to lawyer Khalid Ali. Similar accusations have often been used against those critical of the government of President Abdel Fattah el-Sissi.

  • Form 8.3 - Meggitt plc

    LONDON, May 23, 2022-- FORM 8.3

  • CEO's share-based incentive scheme: Incap's Board of Directors approved share subscriptions

    Incap Corporation Stock exchange release 23 May 2022 at 5.15 p.m. EESTOther information disclosed according to the rules of the Exchange CEO's share-based incentive scheme: Incap's Board of Directors approved share subscriptions On 26 May 2020, the Board of Directors of Incap Corporation (the “Company” or “Incap”) resolved on the establishment of a share-based long-term incentive scheme for Otto Pukk, the CEO of the company, and on 26 April 2022, on its amendment. The CEO may earn a reward based

  • Form 8.3 - John Menzies plc

    LONDON, May 23, 2022-- FORM 8.3

  • Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing

    Paul Friel Elevar Therapeutics today announced the hiring of Paul Friel as chief commercial officer. SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Paul Friel as chief commercial officer. Friel has more than 30 years’ experience in the pharmaceutical industry, including le

  • Form 8.3 - Ultra Electronics Holdings plc

    LONDON, May 23, 2022-- FORM 8.3

  • greymatter.io Graduates from MissionLink’s Spring 2022 Cohort; Joins Esteemed Alumni Network

    ALEXANDRIA, Va., May 23, 2022--greymatter.io Chris Holmes, CEO has graduated from MissionLink.Next, a network for accelerating innovation and advancing National Security solutions.

  • Form 8.3 - GXO Logistics, Inc

    LONDON, May 23, 2022-- FORM 8.3

  • Form 8.3 - Ideagen plc

    LONDON, May 23, 2022-- FORM 8.3

  • Form 8.3 - Clipper Logistics plc

    LONDON, May 23, 2022-- FORM 8.3

  • Form 8.3 - Nitro Bidco Limited (a wholly-owned subsidiary of NortonLifeLock Inc.)

    LONDON, May 23, 2022-- FORM 8.3

  • Transactions in connection with share buyback programme

    Transactions in connection with share buyback programme On 9 February 2022, Pandora announced a new share buyback programme, cf. Company announcement no. 692. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation). The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes. Under the progr

  • We can’t stop staring at Kendall Jenner’s super overlined lips

    Kendall Jenner's Instagram selfie video shows off her glam look featuring super overlined lips for Kourtney Kardashian and Travis Barker's wedding in Italy.